Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
0.00%
)
US TECH 100
23,603.60
(
-0.81%
)
Dow Jones
46,225.15
(
0.00%
)
Brent Oil
108.65
(
1.94%
)
Bitcoin
69,136.85
(
-2.95%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 162994

Wednesday, 08/28/2013 11:20:19 AM

Wednesday, August 28, 2013 11:20:19 AM

Post# of 257257
FDA accepts Pradaxa sNDA for treatment of acute VTE:

http://finance.yahoo.com/news/fda-accepts-boehringer-ingelheims-supplemental-120000505.html

Pradaxa has a pending MAA for acute VTE treatment and secondary prevention in the EU (#msg-89322704).

Xarelto is already approved in the US and EU for the acute-PE subset of the above indication (#msg-81103054), while Eliquis appears to be a shoo-in for FDA approval for treatment of acute VTE and secondary prevention (#msg-89518539), although an sNDA submission has not yet been made.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now